239 related articles for article (PubMed ID: 23131346)
1. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection.
Martín-Gandul C; Pérez-Romero P; Sánchez M; Bernal G; Suárez G; Sobrino M; Merino L; Cisneros JM; Cordero E;
J Clin Virol; 2013 Jan; 56(1):13-8. PubMed ID: 23131346
[TBL] [Abstract][Full Text] [Related]
2. Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients.
Boaretti M; Sorrentino A; Zantedeschi C; Forni A; Boschiero L; Fontana R
J Clin Virol; 2013 Feb; 56(2):124-8. PubMed ID: 23182772
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
Lisboa LF; Preiksaitis JK; Humar A; Kumar D
Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.
Martín-Dávila P; Fortún J; Gutiérrez C; Martí-Belda P; Candelas A; Honrubia A; Barcena R; Martínez A; Puente A; de Vicente E; Moreno S
J Clin Virol; 2005 Jun; 33(2):138-44. PubMed ID: 15911429
[TBL] [Abstract][Full Text] [Related]
5. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2013 May; 57(1):50-3. PubMed ID: 23403239
[TBL] [Abstract][Full Text] [Related]
6. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
7. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
8. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
9. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients.
Sun HY; Cacciarelli TV; Wagener MM; Singh N
Transpl Immunol; 2010 Aug; 23(4):166-9. PubMed ID: 20609386
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
Tan SK; Waggoner JJ; Pinsky BA
J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay.
Furione M; Rognoni V; Cabano E; Baldanti F
J Clin Virol; 2012 Dec; 55(4):317-22. PubMed ID: 22989927
[TBL] [Abstract][Full Text] [Related]
12. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
13. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
15. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients.
Sanghavi SK; Abu-Elmagd K; Keightley MC; St George K; Lewandowski K; Boes SS; Bullotta A; Dare R; Lassak M; Husain S; Kwak EJ; Paterson DL; Rinaldo CR
J Clin Virol; 2008 Aug; 42(4):335-42. PubMed ID: 18495527
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
Benmarzouk-Hidalgo OJ; Cordero E; Martín-Peña A; García-Prado E; Gentil MA; Gomez-Bravo MA; Barrera-Pulido L; Cisneros JM; Perez-Romero P
Antivir Ther; 2009; 14(5):641-7. PubMed ID: 19704166
[TBL] [Abstract][Full Text] [Related]
19. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.
Bravo D; Clari MÁ; Costa E; Muñoz-Cobo B; Solano C; José Remigia M; Navarro D
J Clin Microbiol; 2011 Aug; 49(8):2899-904. PubMed ID: 21697323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]